Feb 21, 2014 8:00am EST SCYNEXIS Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA for Antifungal Agent SCY-078 for Oral Use
Sep 10, 2013 8:20am EDT SCYNEXIS Signs Deal With R-Pharm to Develop and Market Novel Antifungal Compound in Russia and Other Markets
Apr 10, 2013 9:15am EDT SCYNEXIS and Immune Design Collaborate on Innovative Process for Vaccine Production Technology
Nov 11, 2012 4:45pm EST SCYNEXIS’ Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments
